



EMMA

European Multiple Myeloma Academy

Friday 1st – Saturday 2nd
October 2021

24th EMMA-Post IMW 2021

Virtual Meeting

Central Europe Summer Time (CEST)

Chairs:

Jesús F. San-Miguel, Clínica Universidad de Navarra, Pamplona (Spain)

Heinz Ludwig, Wilhelminen Cancer Research Institute, Vienna (Austria)

www.emma-madrid.com

Organized by:



Universidad
de Navarra

Friday, 1st October 2021

Central Europe Summer Time (CEST)

- 09:00 - 09:10 **Opening**
Jesús F. San-Miguel, Heinz Ludwig
- 09:10 - 10:25 **PLENARY SESSION 1: MYELOMA BIOLOGY**
Moderator: Heinz Ludwig
- 09:10 - 09:30 **Genomics in myeloma: pathogenic and clinical implications**
Jill Corre
- 09:30 - 09:50 **How important are epigenetics in MM**
Felipe Prósper
- 09:50 - 10:10 **Druggable myeloma therapeutics. Pathogenetic pathways**
Enrique Ocio
- 10:10 - 10:25 **Experts' discussion around 5 burning questions:**
1. What techniques? Clinical meaning of mutations
2. The number of genetics lesions and percentage of abnormal cells matter for clinical decisions?
3. What is the meaning of genetic changes in MGUS and SMM?
4. Clinical future for epigenetics
5. What are the most relevant pathways and drugs in myeloma?
Discussants: Jill Corre, Felipe Prósper, Enrique Ocio, Pieter Sonneveld
- 10:25 - 10:35 *Break*
- 10:35 - 11:50 **PLENARY SESSION 2: NEW TOOLS FOR TREATMENT MONITORING IN MM PATIENTS**
Moderator: Heinz Ludwig
- 10:35 - 10:55 **MRD**
Bruno Paiva
- 10:55 - 11:15 **Mass spectrometry**
Noemí Puig
- 11:15 - 11:35 **MRI and CT-PET**
Elena Zamagni
- 11:35 - 11:50 **Experts' discussion around 5 burning topics:**
1. New response criteria
2. Optimal MRD technique
3. Prognostic factors or biomarker for treatment
4. Should we stratify patients?
5. Should we implement PET in routine clinical practice?
Discussants: Bruno Paiva, Noemí Puig, Elena Zamagni, Jill Corre
- 11:50 - 12:00 *Break*

12:00 - 13:15 **WORKSHOPS**

- Moderator: Jesús F. San-Miguel
- 12:00 - 12:20 **1. Difficult to treat MM (extramedullary, CNS, oligosecretory, solitary, PCL, biochemical relapse)**
Kwee Yong
- 12:20 - 12:40 **2. MGUS with systemic manifestations**
Joan Bladé
- 12:40 - 13:00 **3. Emergencies and supportive care (cord compression, RI, hyperCa, bone disease)**
Evangelos Terpos
- 13:00 - 13:15 **Questions & discussion**
- 13:15 - 14:00 *Break*
- 14:00 - 14:30 **PLENARY SESSION 3: KEYNOTE LECTURE**
Moderator: Jesús F. San-Miguel
- 14:00 - 14:20 **Infections and myeloma**
Heinz Ludwig
- 14:20 - 14:30 **Questions & discussion**
- 14:30 - 14:40 *Break*
- 14:40 - 15:55 **PLENARY SESSION 4: FRONT LINE TREATMENT FOR YOUNG PATIENTS WITH MM**
Moderator: Jesús F. San-Miguel
- 14:40 - 15:00 **Smoldering MM**
M. Victoria Mateos
- 15:00 - 15:20 **Induction and transplant**
Philippe Moreau
- 15:20 - 15:40 **Consolidation and maintenance**
Pieter Sonneveld
- 15:40 - 15:55 **Experts' discussion on 7 burning topics:**
1. How to define high risk SMM
2. To treat or not to treat SMM
3. Best induction
4. Early vs. late transplant
5. One vs. two
6. Consolidation & maintenance
7. High risk
Discussants: M. Victoria Mateos, Philippe Moreau, Pieter Sonneveld, Joan Bladé
- 15:55 - 16:05 *Break*
- 16:05 - 16:40 **PLENARY SESSION 5: FRONT LINE TREATMENT FOR ELDERLY PATIENTS WITH MM**
Moderator: Heinz Ludwig
- 16:05 - 16:25 **How I treat elderly patients**
Thierry Facon
- 16:25 - 16:40 **Experts' discussion on 5 burning topics:**
1. Optimal combination and duration
2. Maintenance/ continuous
3. Do we need alkylators?
4. High risk
5. Frailty
Discussants: Thierry Facon, M. Victoria Mateos, Enrique Ocio, Kwee Yong

Saturday, 2nd October 2021

Central Europe Summer Time (CEST)

- 09:00 - 09:35 **PLENARY SESSION 6: THE RELAPSED/ REFRACTORY PATIENTS: RECOMMENDATIONS AND CHALLENGES**
Moderator: Jesús F. San-Miguel
- 09:00 - 09:20 **How I treat relapsed patients (without immunotherapy)**
Mario Boccadoro
- 09:20 - 09:35 **Experts' discussion on 5 burning topics:**
1. Biological relapse versus aggressive relapse
2. Early and late relapse and ASCT
3. Triplet versus doublets: is it cost-effective?
4. Optimal sequence for new agents
5. Extramedullary relapse
Discussants: Mario Boccadoro, Meletios A. Dimopoulos, Mohamad Mohty, Paula Rodríguez-Otero
- 09:35 - 09:45 *Break*
- 09:45 - 10:40 **PLENARY SESSION 7: IMMUNOTHERAPY**
Moderator: Heinz Ludwig
- 09:45 - 10:05 **Bases for immunotherapy in MM and novel antibodies**
Hermann Einsele
- 10:05 - 10:25 **Clinical results with CAR-T cells and other adoptive therapies**
Paula Rodríguez-Otero
- 10:25 - 10:40 **Experts' discussion on 6 burning topics:**
1. Role of conjugated antibodies
2. Sequence of anti-BCMA treatments
3. Is CAR-T the future?
4. CAR-T plus anti-myeloma drugs
5. Bispecific antibodies or CAR-T
6. Industry or academia
Discussants: Hermann Einsele, Paula Rodríguez-Otero, Meletios A. Dimopoulos, Mohamad Mohty
- 10:40 - 10:50 *Break*
- 10:50 - 12:05 **PLENARY SESSION 8: HOW I TREAT OTHER MALIGNANT GAMMOPATHIES**
Moderator: Jesús F. San-Miguel, Heinz Ludwig
- 10:50 - 11:10 **Amyloidosis**
Giampaolo Merlini
- 11:10 - 11:30 **Waldenstrom macroglobulinemia**
Meletios A. Dimopoulos
- 11:30 - 11:50 **The relations between academia and industry**
Mohamad Mohty
- 11:50 - 12:05 **Questions & discussion**
- 12:05 - 12:15 **Closing remarks**
Jesús F. San-Miguel, Heinz Ludwig

Organized by:



Universidad de Navarra

List of Faculty

Joan Bladé
Hospital Clínic Universitari, Barcelona (Spain)

Mario Boccadoro
Università degli Studi di Torino, Turin (Italy)

Jill Corre
IUCT Oncopole, Toulouse (France)

Meletios A. Dimopoulos
University Athens School of Medicine, Athens (Greece)

Hermann Einsele
University Hospital Würzburg, Würzburg (Germany)

Thierry Facon
Claude Huriez Hospital, Lille (France)

Heinz Ludwig
Wilhelminen Cancer Research Institute, Vienna (Austria)

M. Victoria Mateos
Hospital Universitario de Salamanca, Salamanca (Spain)

Giampaolo Merlini
Fondazione IRCCS Policlinico San Matteo, Pavia (Italy)

Mohamad Mothy
Saint-Antoine Hospital and University Pierre & Marie Curie, Paris (France)

Philippe Moreau
University Hospital Hôtel-Dieu, Nantes (France)

Enrique Ocio
Hospital Universitario Marqués de Valdecilla, Santander (Spain)

Bruno Paiva
CIMA, Universidad de Navarra, Pamplona (Spain)

Felipe Prósper
Clínica Universidad de Navarra, Pamplona (Spain)

Noemí Puig
Hospital Universitario de Salamanca, Salamanca (Spain)

Paula Rodríguez-Otero
Clínica Universidad de Navarra, Pamplona (Spain)

Jesús F. San-Miguel
Clínica Universidad de Navarra, Pamplona (Spain)

Pieter Sonneveld
Erasmus University Medical Center, Rotterdam (The Netherlands)

Evangelos Terpos
General Hospital of Athens, Athens (Greece)

Kwee Yong
University College London Hospitals NHS Trust, London (UK)

Elena Zamagni
Seragnoli Institute of Hematology, Bologna (Italy)

This meeting is targeted towards myeloma treating physicians who are interested in understanding and discussing the latest developments in myeloma diagnosis and treatment.



Campus Universidad de Navarra

Virtual Meeting

www.emma-madrid.com

Accreditation

An application to the EACCME® for CME accreditation of this event has been submitted

Conference Secretariat:

doctaforum
MEDICAL MARKETING SPECIALISTS | (+34) 91 372 02 03
e-mail: emma@doctaforum.com
www.emma-madrid.com

Organized by:



**Universidad
de Navarra**